Technical Analysis for REPH - Recro Pharma, Inc.

Grade Last Price % Change Price Change
grade A 12.04 -2.35% -0.29
REPH closed down 2.35 percent on Friday, August 23, 2019, on 65 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical REPH trend table...

Date Alert Name Type % Chg
Slingshot Bullish Bullish Swing Setup 0.00%
Wide Bands Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
New 52 Week High Strength -2.35%
Upper Bollinger Band Walk Strength -2.35%
Wide Bands Range Expansion -2.35%
Overbought Stochastic Strength -2.35%
Upper Bollinger Band Touch Strength -2.35%
New 52 Week Closing High Bullish -2.59%
Pocket Pivot Bullish Swing Setup -2.59%

Older signals for REPH ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Recro Pharma, Inc., a clinical stage specialty pharmaceutical company, is engaged in the development of various non-opioid therapeutics for the treatment of pain and related conditions in the United States. The company is developing intranasal formulation of Dexmedetomidine (Dex) for the treatment of post-operative pain and cancer breakthrough pain; sublingual formulation of Dex for the treatment of chronic pain; and Fadolmidine (Fado), a product candidate to treat post-operative pain and neuropathic pain. It has a license agreement with Orion Corporation for the development and commercialization of Dex and Fado. The company was formerly known as Recro Pharma I, Inc. and changed its name to Recro Pharma, Inc. in August 2008. Recro Pharma, Inc. was founded in 2007 and is based in Malvern, Pennsylvania.
Medicine Pain Chronic Pain Perception Stage Specialty Pharmaceutical Imidazoles Neuropathic Pain Sensory Systems
Is REPH a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 12.67
52 Week Low 5.53
Average Volume 206,007
200-Day Moving Average 8.6466
50-Day Moving Average 10.2164
20-Day Moving Average 10.656
10-Day Moving Average 11.463
Average True Range 0.5124
ADX 37.56
+DI 40.9004
-DI 14.6885
Chandelier Exit (Long, 3 ATRs ) 11.1328
Chandelier Exit (Short, 3 ATRs ) 10.6372
Upper Bollinger Band 12.6184
Lower Bollinger Band 8.6936
Percent B (%b) 0.85
BandWidth 36.831832
MACD Line 0.5718
MACD Signal Line 0.3944
MACD Histogram 0.1774
Fundamentals Value
Market Cap 229.47 Million
Num Shares 19.1 Million
EPS -2.12
Price-to-Earnings (P/E) Ratio -5.68
Price-to-Sales 2.35
Price-to-Book 2.89
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 12.85
Resistance 3 (R3) 12.91 12.71 12.72
Resistance 2 (R2) 12.71 12.50 12.68 12.67
Resistance 1 (R1) 12.37 12.37 12.27 12.31 12.62
Pivot Point 12.17 12.17 12.12 12.14 12.17
Support 1 (S1) 11.83 11.96 11.73 11.77 11.46
Support 2 (S2) 11.63 11.83 11.60 11.41
Support 3 (S3) 11.29 11.63 11.37
Support 4 (S4) 11.23